Finding new ways to treat diffuse midline gliomas
Cancer is a sneaky disease. Find one method of treating it successfully, and it finds another way to survive.
May 22, 2023
0
34
Cancer is a sneaky disease. Find one method of treating it successfully, and it finds another way to survive.
May 22, 2023
0
34
Indiana University School of Medicine researchers studying clonal hematopoiesis of indeterminate potential (CHIP), a blood condition that may increase the risk of blood cancer, discovered that obesity was strongly associated ...
May 16, 2023
0
14
Prostate cancer is the second leading cause of death in American men. Understanding the factors that influence patient outcomes is critical for improving treatment and survival rates.
May 8, 2023
0
8
A new Fred Hutchinson Cancer Center study in the journal Obstetrics & Gynecology investigated how endometriosis, uterine leiomyomas (also known as fibroids) and a common intervention for these conditions—hysterectomy—changed ...
May 4, 2023
0
2
Researchers at Baylor College of Medicine and collaborating institutions have identified a strategy cancerous tumors use to remotely disrupt the development of an immune response that could stop their growth.
May 4, 2023
0
138
New research has identified a potential therapeutic target and developed a unique delivery system to treat osteosarcoma, a bone cancer that primarily affects children and adolescents.
Apr 27, 2023
0
38
Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells. These plasma cells are a special type of white blood cells that play an important role in the immune system by producing ...
Apr 27, 2023
0
30
Despite the promise of new medications that promote cancer cell death in people with acute myeloid leukemia, leukemic cells often adopt features that let them evade the drugs' effects within a year.
Apr 24, 2023
0
34
Tisch Cancer Center scientists have developed unique models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a transformative resource to study this cancer and eventually its drug response and drug resistance. ...
Apr 17, 2023
0
2
For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen deprivation therapy (ADT), and doublet therapy ...
Apr 12, 2023
0
9